JP2019522032A - 前立腺癌の治療方法 - Google Patents

前立腺癌の治療方法 Download PDF

Info

Publication number
JP2019522032A
JP2019522032A JP2019504790A JP2019504790A JP2019522032A JP 2019522032 A JP2019522032 A JP 2019522032A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019522032 A JP2019522032 A JP 2019522032A
Authority
JP
Japan
Prior art keywords
prostate cancer
nilaparib
treatment
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019504790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522032A5 (enExample
Inventor
ゴッタルディス，マルコ
ホーキンス，レベッカ
スナイダー，リンダ
エイチ． ヤマダ，ダグラス
エイチ． ヤマダ，ダグラス
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2019522032A publication Critical patent/JP2019522032A/ja
Publication of JP2019522032A5 publication Critical patent/JP2019522032A5/ja
Priority to JP2022084991A priority Critical patent/JP7569353B2/ja
Priority to JP2024117499A priority patent/JP7752220B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504790A 2016-07-29 2017-07-28 前立腺癌の治療方法 Withdrawn JP2019522032A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022084991A JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US62/368,466 2016-07-29
US201662369239P 2016-08-01 2016-08-01
US62/369,239 2016-08-01
PCT/US2017/044413 WO2018023017A1 (en) 2016-07-29 2017-07-28 Methods of treating prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084991A Division JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Publications (2)

Publication Number Publication Date
JP2019522032A true JP2019522032A (ja) 2019-08-08
JP2019522032A5 JP2019522032A5 (enExample) 2020-09-03

Family

ID=59649991

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504790A Withdrawn JP2019522032A (ja) 2016-07-29 2017-07-28 前立腺癌の治療方法
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A Active JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法
JP2024117499A Active JP7752220B2 (ja) 2016-07-29 2024-07-23 前立腺癌の治療方法

Country Status (32)

Country Link
US (8) US20180028521A1 (enExample)
EP (2) EP3490560B1 (enExample)
JP (3) JP2019522032A (enExample)
KR (2) KR20190033599A (enExample)
CN (3) CN109640991A (enExample)
AU (2) AU2017302660B2 (enExample)
BR (1) BR112019001398A2 (enExample)
CA (1) CA3031705A1 (enExample)
CO (1) CO2019000753A2 (enExample)
DK (1) DK3490560T3 (enExample)
DO (1) DOP2019000019A (enExample)
ES (1) ES3014630T3 (enExample)
FI (2) FI3490560T3 (enExample)
FR (1) FR25C1027I1 (enExample)
HR (1) HRP20250157T1 (enExample)
HU (2) HUE070253T2 (enExample)
IL (2) IL322013A (enExample)
LT (2) LT3490560T (enExample)
MA (1) MA45780B1 (enExample)
MX (2) MX2019001224A (enExample)
NI (1) NI201900009A (enExample)
PE (1) PE20190403A1 (enExample)
PH (1) PH12019500135A1 (enExample)
PL (1) PL3490560T3 (enExample)
PT (1) PT3490560T (enExample)
RS (1) RS66574B1 (enExample)
SG (1) SG11201900361RA (enExample)
SI (1) SI3490560T1 (enExample)
SM (1) SMT202500082T1 (enExample)
SV (1) SV2019005822A (enExample)
UA (1) UA124972C2 (enExample)
WO (1) WO2018023017A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX394062B (es) 2016-06-29 2025-03-19 Tesaro Inc Métodos para el tratamiento del cáncer ovárico.
ES3014630T3 (en) 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
TW201929902A (zh) * 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
EP3793541A4 (en) * 2018-05-16 2022-03-02 GTx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP4373491A1 (en) * 2021-07-19 2024-05-29 JANSSEN Pharmaceutica NV Treatment of metastatic castration-resistant prostate cancer with niraparib

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
EP0227826B1 (en) 1985-08-02 1989-10-25 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
DE4021433A1 (de) 1990-07-04 1992-01-09 Schering Ag Antiandrogene mit steroid(3,2-c)pyrazol-struktur
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
WO1995009178A1 (en) 1993-09-30 1995-04-06 British Technology Group Limited Synthesis of 17-(3-pyridyl) steroids
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
JP4172726B2 (ja) 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
EP1140194A2 (en) 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
JP2003525254A (ja) 2000-03-02 2003-08-26 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 併用化学療法
WO2001081364A1 (en) 2000-04-24 2001-11-01 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives
EP1676577A1 (en) 2000-05-15 2006-07-05 Celgene Corporation Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
AU2000260772A1 (en) 2000-07-05 2002-01-14 Bryan Muehlberger Systems and methods of facilitating electronic payment transactions
AU2687702A (en) 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
SI1598338T1 (sl) 2001-04-18 2009-06-30 Euro Celtique Sa Derivati 1-(4-piperidinil)-1,3-dihidro-2H-indol-2-ona in sorodne spojine kot analogi nociceptina in ligandi ORL1 za zdravljenje bolečine
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
ES2340441T3 (es) 2001-04-18 2010-06-02 Euro-Celtique S.A. Compuestos de octahidrobencimidazolona como analgesicos.
US6838584B2 (en) 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
WO2004016753A2 (en) 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US7186723B2 (en) 2001-08-30 2007-03-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
WO2003037252A2 (en) 2001-10-30 2003-05-08 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
WO2005016236A2 (en) 2003-05-06 2005-02-24 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DK1472225T3 (da) 2002-02-01 2010-08-09 Euro Celtique Sa 2-Piperazinpyridiner, som er anvendelige til behandling af smerte
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
CA2481241C (en) 2002-04-08 2010-07-27 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
EP1927858B1 (en) 2002-04-29 2013-01-09 Euro-Celtique S.A. Conformationally constrained peptides that bind the ORL-1 receptor
WO2003092595A2 (en) 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
DK1556354T3 (da) 2002-06-28 2008-06-02 Euro Celtique Sa Terapeutiske piperazinderivater, der er egnede til behandling af smerter
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7053091B2 (en) 2002-12-17 2006-05-30 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050054620A1 (en) 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
GEP20094675B (en) 2003-07-24 2009-05-10 Euro Celtique Sa Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PL1942106T3 (pl) 2003-08-01 2012-02-29 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
CN1842515A (zh) 2003-08-27 2006-10-04 默克弗罗斯特加拿大有限公司 组织蛋白酶抑制剂
SI1664016T1 (sl) 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
WO2005030766A1 (en) 2003-09-22 2005-04-07 Euro-Celtique S.A. Phenyl - carboxamide compounds useful for treating pain
WO2005039587A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
WO2005107801A2 (en) 2004-04-29 2005-11-17 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
WO2006027266A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
EP1674479A1 (en) 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
BRPI0612925A2 (pt) 2005-04-27 2010-12-07 Univ Florida Res Foudation Inc uso de um composto, composição farmacêutica e kit
WO2006116217A2 (en) 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
WO2007113596A1 (en) 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
AU2007300734A1 (en) 2006-06-02 2008-04-03 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RNA nanoparticles and nanotubes
CN101511361A (zh) 2006-06-30 2009-08-19 先灵公司 使用增强p53活性的取代哌啶的方法
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
RS52956B (sr) 2006-08-25 2014-02-28 Janssen Oncology Inc. Kompozicije za tretman kancera
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2008127290A2 (en) 2006-10-12 2008-10-23 The Johns Hopkins University Alginate and alginate lyase compositions and methods of use
EP2081565A2 (en) 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
MX2009007200A (es) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
WO2008109740A2 (en) 2007-03-06 2008-09-12 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
TWI443102B (zh) 2008-03-31 2014-07-01 Genentech Inc 苯并哌喃及苯并氧呯ｐｉ３ｋ抑制劑化合物及其使用方法
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
MY180834A (en) * 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
WO2014150000A1 (en) 2013-03-21 2014-09-25 Isp Investments Inc. Diacetylene film sensitized with photoinitiator and applications of the film
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR20160058774A (ko) * 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US9987275B2 (en) 2014-04-23 2018-06-05 The Brigham And Women's Hospital, Inc. Targeting PARP1 for treatment of TSC and cancers
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
ES3014630T3 (en) 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
US11702443B2 (en) 2016-10-04 2023-07-18 Pop Test Oncology Llc Therapeutic agents and methods
EP3534910A4 (en) 2016-10-04 2020-11-25 Pop Test Oncology LLC THERAPEUTIC METHODS AND AGENTS
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
KR20200068689A (ko) 2017-10-11 2020-06-15 얀센 온콜로지 인크 안드로겐 박탈 요법과 함께 아비라테론 아세테이트 + 프레드니손을 투여하여 전립선암을 치료하는 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUGS OF THE FUTURE, vol. 38, no. 10, JPN6021015328, 2013, pages 679 - 685, ISSN: 0004493217 *
LANCET ONCOL, vol. 14, JPN6021015330, 2013, pages 882 - 892, ISSN: 0004493218 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 373, no. 18, JPN6021015333, 2015, pages 1697 - 1708, ISSN: 0004493219 *

Also Published As

Publication number Publication date
AU2017302660A1 (en) 2019-01-24
PH12019500135A1 (en) 2019-10-28
MA45780A (fr) 2019-06-05
ES3014630T3 (en) 2025-04-23
SV2019005822A (es) 2019-03-28
LTPA2025528I1 (enExample) 2025-08-11
AU2017302660B2 (en) 2023-04-20
PT3490560T (pt) 2025-03-20
US11986468B2 (en) 2024-05-21
US20220071979A1 (en) 2022-03-10
AU2023202813A1 (en) 2023-05-25
CN119606966A (zh) 2025-03-14
RS66574B1 (sr) 2025-03-31
US20230098047A1 (en) 2023-03-30
CN119606965A (zh) 2025-03-14
FR25C1027I1 (fr) 2025-09-19
CO2019000753A2 (es) 2019-02-08
US20240000766A1 (en) 2024-01-04
HUE070253T2 (hu) 2025-05-28
US11986469B2 (en) 2024-05-21
MX2019001224A (es) 2019-06-03
DOP2019000019A (es) 2019-09-30
CA3031705A1 (en) 2018-02-01
EP3490560A1 (en) 2019-06-05
NI201900009A (es) 2019-05-10
KR20190033599A (ko) 2019-03-29
MA45780B1 (fr) 2025-03-28
MX2023011187A (es) 2023-10-02
US12383543B2 (en) 2025-08-12
IL322013A (en) 2025-09-01
DK3490560T3 (da) 2025-02-17
KR20240115925A (ko) 2024-07-26
SG11201900361RA (en) 2019-02-27
IL264443A (en) 2019-02-28
WO2018023017A1 (en) 2018-02-01
US20230149380A1 (en) 2023-05-18
LT3490560T (lt) 2025-02-25
PL3490560T3 (pl) 2025-03-24
SMT202500082T1 (it) 2025-03-12
US11992486B2 (en) 2024-05-28
US20230078160A1 (en) 2023-03-16
US11986470B2 (en) 2024-05-21
FI3490560T3 (fi) 2025-02-27
EP4552698A3 (en) 2025-07-30
JP7752220B2 (ja) 2025-10-09
HUS2500030I1 (hu) 2025-08-28
US20220071980A1 (en) 2022-03-10
US20190022079A1 (en) 2019-01-24
BR112019001398A2 (pt) 2019-05-07
EP4552698A2 (en) 2025-05-14
CN109640991A (zh) 2019-04-16
HRP20250157T1 (hr) 2025-03-28
FIC20250026I1 (fi) 2025-07-21
US20180028521A1 (en) 2018-02-01
SI3490560T1 (sl) 2025-04-30
JP2022122920A (ja) 2022-08-23
UA124972C2 (uk) 2021-12-22
US11207311B2 (en) 2021-12-28
JP2024150638A (ja) 2024-10-23
EP3490560B1 (en) 2025-01-22
PE20190403A1 (es) 2019-03-13
JP7569353B2 (ja) 2024-10-17

Similar Documents

Publication Publication Date Title
JP7752220B2 (ja) 前立腺癌の治療方法
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
EA049291B1 (ru) Способы лечения рака предстательной железы
EA040279B1 (ru) Способы лечения рака предстательной железы
HK40007092A (en) Methods of treating prostate cancer
BR122024017981A2 (pt) Composição, forma de dosagem, produto e usos de niraparibe no tratamento de câncer de próstata
BR122024017955A2 (pt) Usos de niraparibe no tratamento de câncer de próstata metastático sensível à castração
US20250213563A1 (en) Substituted pyrimidin-4(3h)-ones for use in treating cancer
CN118632695A (zh) 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220525

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220607

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240219